Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries
WithdrawnPhase 4NCT05364099
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the effectiveness and safety of using suprascapular nerve block for individuals with chronic spinal cord injury who have chronic shoulder pain.
Study details
- Official title
- Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries
- Conditions
- Interventions
- Drug: Lidocaine 1% Injectable Solution
- Drug: Triamcinolone Injection
- Procedure: Suprascapular Nerve Block
- Sponsor
- University of Miami
- Start date
- 2023-11-27
- Primary completion
- 2024-01-01
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1\. Male or female, 18-70 years of age, inclusive. 2 Neurological impairment secondary to SCI that occurred at least twelve (12) months prior to the Screening Visit; neurological level of injury between C6 and L5, inclusive. 3\. Non-ambulatory, except for exercise or therapy purposes. 4. Uses a manual wheelchair. 5 History of chronic shoulder pain for ≥6 months that has been unresponsive to conservative treatment (e.g. physical therapy, pharmacological agents), and is rated as ≥4 out of 10 on an 11-point Numeric Rating Scale (NRS) (0 = "no pain"; 10 = "most intense pain imaginable") for average shoulder pain intensity during the week leading up to the Screening Visit. 6\. Able and willing to comply with the protocol. 7. Able to give voluntary informed consent prior to the performance of any study-specific procedures. Exclusion Criteria: 1. Contra-indications to the procedure (e.g. infection, coagulopathy) 2. History of active cancer within 5 years 3. Adhesive capsulitis 4. Prior history of regenerative medicine intervention 5. Glucocorticoid injection within the past four weeks 6. Any medical condition, including psychiatric illness, which would interfere with the interpretation of the study results or the conduct of the study
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05364099